Artemisinin-based combination therapy for ... - The Cochrane Library

More documents

Recommendations

Info

$Interventions for treating proximal humeral fractures in adults (Review)$

Analysis 6.7. Comparison 6 Artesunate plus mefloquine vs Artemether-lumefantrine, Outcome 7 Gametocyte carriage. Review: Artemisinin-based combination therapy for treating uncomplicated malaria Comparison: 6 Artesunate plus mefloquine vs Artemether-lumefantrine Outcome: 7 Gametocyte carriage Study or subgroup AS+MQ AL6 Risk Ratio Weight Risk Ratio 1 Gametocyte carriage day 0 n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI Faye 2003 SEN 0/145 4/149 100.0 % 0.11 [ 0.01, 2.10 ] Subtotal (95% CI) 145 149 100.0 % 0.11 [ 0.01, 2.10 ] Total events: 0 (AS+MQ), 4 (AL6) Heterogeneity: not applicable Test for overall effect: Z = 1.46 (P = 0.14) 2 Gametocyte carriage day 3 Faye 2003 SEN 3/145 9/149 81.6 % 0.34 [ 0.09, 1.24 ] Van den Broek 2003a BGD 3/121 2/121 18.4 % 1.50 [ 0.26, 8.82 ] Subtotal (95% CI) 266 270 100.0 % 0.56 [ 0.21, 1.48 ] Total events: 6 (AS+MQ), 11 (AL6) Heterogeneity: Chi 2 = 1.75, df = 1 (P = 0.19); I 2 =43% Test for overall effect: Z = 1.17 (P = 0.24) 3 Gametocyte carriage day 7 Stohrer 2003 LAO 5/53 6/47 35.9 % 0.74 [ 0.24, 2.26 ] Van den Broek 2003a BGD 1/121 2/121 11.3 % 0.50 [ 0.05, 5.44 ] Faye 2003 SEN 0/145 9/149 52.9 % 0.05 [ 0.00, 0.92 ] Subtotal (95% CI) 319 317 100.0 % 0.35 [ 0.14, 0.85 ] Total events: 6 (AS+MQ), 17 (AL6) Heterogeneity: Chi 2 = 3.46, df = 2 (P = 0.18); I 2 =42% Test for overall effect: Z = 2.31 (P = 0.021) 4 Gametocyte carriage day 14 Faye 2003 SEN 0/145 4/149 89.9 % 0.11 [ 0.01, 2.10 ] Van den Broek 2003a BGD 1/121 0/121 10.1 % 3.00 [ 0.12, 72.92 ] Subtotal (95% CI) 266 270 100.0 % 0.41 [ 0.08, 2.10 ] Total events: 1 (AS+MQ), 4 (AL6) Heterogeneity: Chi 2 = 2.24, df = 1 (P = 0.13); I 2 =55% Test for overall effect: Z = 1.08 (P = 0.28) 0.001 0.01 0.1 1 10 100 1000 Favours ASMQ Favours AL Artemisinin-based combination therapy for treating uncomplicated malaria (Review) Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. 160
Analysis 6.8. Comparison 6 Artesunate plus mefloquine vs Artemether-lumefantrine, Outcome 8 Serious adverse events (including deaths). Review: Artemisinin-based combination therapy for treating uncomplicated malaria Comparison: 6 Artesunate plus mefloquine vs Artemether-lumefantrine Outcome: 8 Serious adverse events (including deaths) Study or subgroup AS+MQ AL6 Risk Ratio Risk Ratio n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI Van Vugt 1998 THA 1/50 1/150 3.00 [ 0.19, 47.08 ] Lefevre 1999 THA 0/55 0/164 0.0 [ 0.0, 0.0 ] Hutagalung 2002 THA 0/245 0/245 0.0 [ 0.0, 0.0 ] Stohrer 2003 LAO 1/55 1/53 0.96 [ 0.06, 15.01 ] Mayxay 2003 LAO 3/110 0/110 7.00 [ 0.37, 133.94 ] Van den Broek 2003a BGD 0/121 0/121 0.0 [ 0.0, 0.0 ] Faye 2003 SEN 0/145 0/149 0.0 [ 0.0, 0.0 ] Total (95% CI) 781 992 2.96 [ 0.64, 13.76 ] Total events: 5 (AS+MQ), 2 (AL6) Heterogeneity: Chi 2 = 0.97, df = 2 (P = 0.62); I 2 =0.0% Test for overall effect: Z = 1.39 (P = 0.17) Artemisinin-based combination therapy for treating uncomplicated malaria (Review) Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. 0.005 0.1 1 10 200 Favours ASMQ Favours AL 161
Page 1 and 2:
Artemisinin-based combination thera
Page 3 and 4:
Analysis 2.2. Comparison 2 Dihydroa
Page 5 and 6:
Analysis 10.5. Comparison 10 Arteme
Page 7 and 8:
[Intervention Review] Artemisinin-b
Page 9 and 10:
B A C K G R O U N D Malaria is a di
Page 11 and 12:
drugs and the treatment comparisons
Page 13 and 14:
this analysis into participants who
Page 15 and 16:
Figure 1. Methodological quality su
Page 17 and 18:
confidence intervals of the estimat
Page 19 and 20:
Anaemia Hasugian 2005 IDN found tha
Page 21 and 22:
Three trials report significantly m
Page 23 and 24:
or those treated for P. vivax at ba
Page 25 and 26:
Early vomiting Not reported. D I S
Page 27 and 28:
Figure 4. Olliaro-Vaillant plot. Da
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Figure 10. Olliaro-Vaillant plot. D
Page 35 and 36:
of findings tables’. For these ta
Page 37 and 38:
Huambo and Bie provinces, central A
Page 39 and 40:
References to studies excluded from
Page 41 and 42:
Adjuik 2004 Adjuik M, Babiker A, Ga
Page 43 and 44:
C H A R A C T E R I S T I C S O F S
Page 45 and 46:
Ashley 2003a THA (Continued) Outcom
Page 47 and 48:
Ashley 2003b THA (Continued) Alloca
Page 49 and 50:
Ashley 2005 THA (Continued) Exclusi
Page 51 and 52:
Bonnet 2004 GIN (Continued) Item Au
Page 53 and 54:
Bukirwa 2005 UGA Methods Trial desi
Page 55 and 56:
Djimde 2004 MLI (Continued) • AS
Page 57 and 58:
Dorsey 2006 UGA (Continued) Item Au
Page 59 and 60:
Fanello 2004 RWA Methods Trial desi
Page 61 and 62:
Faye 2003 SEN (Continued) Outcomes
Page 63 and 64:
Grande 2005 PER (Continued) Allocat
Page 65 and 66:
Guthmann 2004 AGO (Continued) All d
Page 67 and 68:
Hasugian 2005 IDN Methods Trial des
Page 69 and 70:
Hutagalung 2002 THA (Continued) 5.
Page 71 and 72:
Janssens 2003 KHM (Continued) Free
Page 73 and 74:
Karema 2004 RWA (Continued) Interve
Page 75 and 76:
Karunajeewa 2007 PNG (Continued) Ri
Page 77 and 78:
Kobbe 2007 GHA (Continued) Exclusio
Page 79 and 80:
Koram 2003 GHA (Continued) Adequate
Page 81 and 82:
Martensson 2003 TZA Methods Trial d
Page 83 and 84:
Mayxay 2003 LAO (Continued) 1. Feve
Page 85 and 86:
Menard 2006 MDG Methods Trial desig
Page 87 and 88:
Mens 2007 KEN (Continued) Risk of b
Page 89 and 90:
Mutabingwa 2004 TZA (Continued) •
Page 91 and 92:
Owusu-Agyei 2006 GHA (Continued) Fr
Page 93 and 94:
Sagara 2005b MLI (Continued) • 25
Page 95 and 96:
Smithuis 2004 MMR (Continued) Risk
Page 97 and 98:
Stohrer 2003 LAO Methods Trial desi
Page 99 and 100:
Swarthout 2004 ZAR (Continued) Note
Page 101 and 102:
Tran 2002 VNM Methods Trial design:
Page 103 and 104:
Van den Broek 2003a BGD (Continued)
Page 105 and 106:
Van Vugt 1998 THA Methods Trial des
Page 107 and 108:
Yeka 2004 UGA (Continued) Risk of b
Page 109 and 110:
Yeka 2007 UGA (Continued) Free of o
Page 111 and 112:
Zongo 2007 BFA (Continued) Novartis
Page 113 and 114:
(Continued) Fofana 2005 Conference
Page 115 and 116: D A T A A N D A N A L Y S E S Compa
Page 117 and 118: 2.2 Asia 1 317 Risk Ratio (M-H, Fix
Page 119 and 120: Comparison 5. Dihydroartemisinin-pi
Page 121 and 122: Comparison 8. Artesunate plus meflo
Page 123 and 124: Comparison 10. Artemether-lumefantr
Page 125 and 126: Comparison 12. Artesunate plus amod
Page 127 and 128: 5.2 DHA-P 3 doses 3 1116 Risk Ratio
Page 129 and 130: Comparison 21. How does Artesunate
Page 131 and 132: Analysis 1.3. Comparison 1 Dihydroa
Page 137 and 138: (... Continued) Study or subgroup D
Page 139 and 140: Analysis 1.12. Comparison 1 Dihydro
Page 141 and 142: (... Continued) Study or subgroup D
Page 163 and 164: (... Continued) Study or subgroup A
Page 165: Analysis 6.6. Comparison 6 Artesuna
Page 169 and 170: Analysis 7.2. Comparison 7 Artesuna
Page 171 and 172: Analysis 8.2. Comparison 8 Artesuna
Page 173 and 174: Analysis 9.2. Comparison 9 Artemeth
Page 177 and 178: Analysis 9.8. Comparison 9 Artemeth
Page 183 and 184: Analysis 10.2. Comparison 10 Arteme
Page 197 and 198: Analysis 12.2. Comparison 12 Artesu
Page 207 and 208: Analysis 14.2. Comparison 14 Dihydr
Page 217 and 218:
(... Continued) Study or subgroup D
Page 219 and 220:
Analysis 20.1. Comparison 20 How do
Page 221 and 222:
Analysis 21.1. Comparison 21 How do
Page 223 and 224:
(Continued) 2. How does artesunate
Page 225 and 226:
(Continued) Sensitivity analysis 1
Page 227 and 228:
(Continued) Smithuis 2004 MMR (652
Page 229 and 230:
Dihydroartemisinin-piperaquine vs A
Page 231 and 232:
(Continued) Mayxay 2003 LAO (220 pa
Page 233 and 234:
Artesunate plus mefloquine vs Amodi
Page 235 and 236:
(Continued) Faye 2003 SEN (509 part
Page 237 and 238:
Artemether-lumefantrine vs Artesuna
Page 239 and 240:
(Continued) Zongo 2005 BFA (521 par
Page 241 and 242:
(Continued) Faye 2003 SEN (521 part
Page 243 and 244:
PCR = polymerase chain reaction PCV
Page 245 and 246:
(Continued) Proportion with anaemia
Page 247 and 248:
(Continued) Vivax efficacy: P. viva
Page 249 and 250:
(Continued) Efficacy: Total Failure
Page 251 and 252:
(Continued) Outcomes Illustrative c
Page 253 and 254:
Page 255 and 256:
(Continued) GRADE Working Group gra
Page 257 and 258:
Footnotes 1 Data were also availabl
Page 259 and 260:
8 Very serious imprecision: There w
Page 261 and 262:
Page 263 and 264:
(Continued) justed Vivax efficacy:
Page 265 and 266:
(Continued) Harms: Serious adverse
Page 267 and 268:
(Continued) Harms: Early vomiting -
Page 269 and 270:
1 Dorsey 2006 UGA; Faye 2003 SEN; K
show all

Artemisinin-based combination therapy for ... - The Cochrane Library

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?